| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 57 | 2024 | 2096 | 6.110 |
Why?
|
| Cardiovascular Diseases | 26 | 2024 | 1727 | 3.790 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 30 | 2014 | 127 | 3.170 |
Why?
|
| Muscle, Smooth, Vascular | 14 | 2016 | 411 | 2.900 |
Why?
|
| Hypoglycemic Agents | 24 | 2023 | 1013 | 2.700 |
Why?
|
| Mitochondria, Muscle | 8 | 2021 | 93 | 2.480 |
Why?
|
| Insulin Resistance | 29 | 2024 | 1072 | 2.330 |
Why?
|
| Diabetes Mellitus | 11 | 2023 | 900 | 2.120 |
Why?
|
| Mitochondria | 11 | 2022 | 747 | 1.910 |
Why?
|
| Endothelium, Vascular | 12 | 2022 | 847 | 1.770 |
Why?
|
| Blood Vessels | 5 | 2018 | 180 | 1.750 |
Why?
|
| Insulin | 27 | 2023 | 2080 | 1.680 |
Why?
|
| Diabetic Angiopathies | 10 | 2017 | 244 | 1.570 |
Why?
|
| Exercise | 22 | 2022 | 1644 | 1.540 |
Why?
|
| Aorta | 9 | 2018 | 386 | 1.530 |
Why?
|
| Microcirculation | 7 | 2018 | 135 | 1.490 |
Why?
|
| Metformin | 6 | 2022 | 276 | 1.480 |
Why?
|
| Exercise Tolerance | 9 | 2024 | 213 | 1.410 |
Why?
|
| Microvessels | 4 | 2018 | 68 | 1.370 |
Why?
|
| Adaptation, Physiological | 6 | 2021 | 483 | 1.350 |
Why?
|
| Thiazolidinediones | 11 | 2021 | 142 | 1.310 |
Why?
|
| Myocytes, Smooth Muscle | 6 | 2016 | 236 | 1.290 |
Why?
|
| Diabetes Mellitus, Type 1 | 19 | 2022 | 3256 | 1.220 |
Why?
|
| Muscle, Skeletal | 17 | 2023 | 1473 | 1.220 |
Why?
|
| Glucose | 13 | 2022 | 897 | 1.180 |
Why?
|
| Metabolic Syndrome | 9 | 2019 | 321 | 1.140 |
Why?
|
| Models, Cardiovascular | 3 | 2017 | 178 | 1.130 |
Why?
|
| Vascular Stiffness | 5 | 2023 | 407 | 1.110 |
Why?
|
| Blood Glucose | 21 | 2024 | 1829 | 1.090 |
Why?
|
| Hyperglycemia | 4 | 2017 | 292 | 1.080 |
Why?
|
| Catechin | 3 | 2022 | 23 | 1.080 |
Why?
|
| Rats | 36 | 2023 | 4958 | 1.070 |
Why?
|
| Oxidative Stress | 11 | 2022 | 1076 | 1.030 |
Why?
|
| Obesity | 17 | 2023 | 2508 | 1.030 |
Why?
|
| Oxygen Consumption | 18 | 2021 | 588 | 1.000 |
Why?
|
| Glucose Intolerance | 2 | 2024 | 136 | 0.990 |
Why?
|
| Diabetic Neuropathies | 2 | 2023 | 79 | 0.990 |
Why?
|
| Nitric Oxide Synthase Type III | 6 | 2020 | 184 | 0.950 |
Why?
|
| Glucagon-Like Peptide 1 | 6 | 2020 | 101 | 0.950 |
Why?
|
| Oxygen | 3 | 2018 | 854 | 0.950 |
Why?
|
| Hypertension | 5 | 2022 | 1056 | 0.900 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 5 | 2021 | 72 | 0.860 |
Why?
|
| Oxidative Phosphorylation | 5 | 2021 | 155 | 0.860 |
Why?
|
| Humans | 121 | 2024 | 114709 | 0.860 |
Why?
|
| Sex Factors | 7 | 2022 | 1715 | 0.810 |
Why?
|
| Drug Design | 1 | 2023 | 148 | 0.810 |
Why?
|
| Vascular Diseases | 2 | 2022 | 230 | 0.800 |
Why?
|
| Cardiorespiratory Fitness | 3 | 2019 | 35 | 0.790 |
Why?
|
| Insulins | 1 | 2022 | 32 | 0.780 |
Why?
|
| Animals | 66 | 2023 | 31709 | 0.750 |
Why?
|
| Rats, Wistar | 6 | 2023 | 368 | 0.690 |
Why?
|
| Diabetes Mellitus, Experimental | 3 | 2016 | 160 | 0.690 |
Why?
|
| Physical Conditioning, Animal | 3 | 2018 | 194 | 0.690 |
Why?
|
| Cardiovascular System | 3 | 2024 | 125 | 0.680 |
Why?
|
| Blood Flow Velocity | 6 | 2018 | 387 | 0.660 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 2 | 2020 | 89 | 0.660 |
Why?
|
| Motor Activity | 3 | 2015 | 640 | 0.660 |
Why?
|
| Fatty Acids, Nonesterified | 6 | 2016 | 151 | 0.640 |
Why?
|
| Pterins | 1 | 2018 | 8 | 0.630 |
Why?
|
| Male | 61 | 2023 | 55609 | 0.600 |
Why?
|
| Leadership | 1 | 2021 | 292 | 0.600 |
Why?
|
| Adipocytes | 7 | 2001 | 188 | 0.600 |
Why?
|
| Vasodilation | 7 | 2022 | 419 | 0.580 |
Why?
|
| Sex Characteristics | 9 | 2023 | 641 | 0.580 |
Why?
|
| Women's Health | 3 | 2020 | 271 | 0.580 |
Why?
|
| Atherosclerosis | 3 | 2011 | 341 | 0.560 |
Why?
|
| Arterioles | 2 | 2016 | 39 | 0.550 |
Why?
|
| Cell Division | 7 | 2009 | 758 | 0.550 |
Why?
|
| Carotid Arteries | 1 | 2018 | 180 | 0.550 |
Why?
|
| Metabolomics | 2 | 2020 | 521 | 0.550 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 4 | 2021 | 44 | 0.540 |
Why?
|
| Hemorheology | 1 | 2016 | 20 | 0.530 |
Why?
|
| Nitric Oxide | 3 | 2022 | 823 | 0.530 |
Why?
|
| Glycocalyx | 1 | 2016 | 18 | 0.530 |
Why?
|
| Models, Biological | 4 | 2020 | 1621 | 0.510 |
Why?
|
| Diabetes Complications | 2 | 2020 | 211 | 0.510 |
Why?
|
| Capillaries | 1 | 2016 | 91 | 0.510 |
Why?
|
| Needs Assessment | 1 | 2018 | 314 | 0.510 |
Why?
|
| Female | 59 | 2023 | 59523 | 0.510 |
Why?
|
| Epidemics | 4 | 2023 | 69 | 0.510 |
Why?
|
| Software | 2 | 2018 | 530 | 0.500 |
Why?
|
| Risk Factors | 16 | 2022 | 8634 | 0.490 |
Why?
|
| Adamantane | 1 | 2015 | 16 | 0.480 |
Why?
|
| Cell Respiration | 3 | 2020 | 74 | 0.480 |
Why?
|
| Dipeptides | 1 | 2015 | 48 | 0.480 |
Why?
|
| Adipose Tissue | 6 | 2021 | 545 | 0.460 |
Why?
|
| Regional Blood Flow | 7 | 2020 | 424 | 0.450 |
Why?
|
| Diabetic Cardiomyopathies | 4 | 2020 | 34 | 0.430 |
Why?
|
| Biomedical Research | 2 | 2018 | 585 | 0.430 |
Why?
|
| Mitochondrial Dynamics | 1 | 2013 | 22 | 0.420 |
Why?
|
| Overweight | 3 | 2023 | 472 | 0.420 |
Why?
|
| Disease Models, Animal | 8 | 2018 | 3535 | 0.420 |
Why?
|
| Adolescent | 26 | 2023 | 17855 | 0.390 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 5 | 2005 | 213 | 0.390 |
Why?
|
| Patient-Centered Care | 1 | 2017 | 473 | 0.390 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2015 | 685 | 0.380 |
Why?
|
| Tetrazoles | 1 | 2011 | 32 | 0.380 |
Why?
|
| Phosphodiesterase 3 Inhibitors | 1 | 2011 | 13 | 0.380 |
Why?
|
| Glucose Tolerance Test | 3 | 2024 | 343 | 0.370 |
Why?
|
| Hyperinsulinism | 5 | 2019 | 103 | 0.370 |
Why?
|
| Signal Transduction | 8 | 2022 | 4516 | 0.370 |
Why?
|
| Endothelial Cells | 1 | 2016 | 687 | 0.370 |
Why?
|
| Pulse Wave Analysis | 5 | 2023 | 207 | 0.370 |
Why?
|
| Phosphorylation | 16 | 2013 | 1569 | 0.360 |
Why?
|
| Exercise Therapy | 3 | 2022 | 352 | 0.350 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2009 | 608 | 0.350 |
Why?
|
| Cell Nucleus | 6 | 2016 | 554 | 0.350 |
Why?
|
| Promoter Regions, Genetic | 5 | 2003 | 1131 | 0.350 |
Why?
|
| Cell Movement | 4 | 2011 | 869 | 0.340 |
Why?
|
| Hypoglycemia | 1 | 2014 | 387 | 0.340 |
Why?
|
| Aging | 2 | 2018 | 1618 | 0.340 |
Why?
|
| Hyperlipidemias | 3 | 2017 | 121 | 0.340 |
Why?
|
| Rats, Sprague-Dawley | 9 | 2013 | 2218 | 0.330 |
Why?
|
| Lipoproteins, LDL | 1 | 2010 | 128 | 0.330 |
Why?
|
| Mentoring | 2 | 2022 | 100 | 0.330 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 3 | 2021 | 42 | 0.330 |
Why?
|
| Trans-Activators | 2 | 2001 | 367 | 0.320 |
Why?
|
| Pulmonary Artery | 6 | 2013 | 1016 | 0.320 |
Why?
|
| Sirtuin 3 | 2 | 2020 | 52 | 0.320 |
Why?
|
| Insulin-Like Growth Factor I | 3 | 2000 | 286 | 0.320 |
Why?
|
| Cells, Cultured | 14 | 2011 | 3886 | 0.310 |
Why?
|
| Ventricular Dysfunction, Left | 3 | 2020 | 358 | 0.300 |
Why?
|
| Hemodynamics | 3 | 2021 | 1012 | 0.290 |
Why?
|
| Leg | 2 | 2021 | 225 | 0.290 |
Why?
|
| Superoxides | 2 | 2020 | 214 | 0.290 |
Why?
|
| Adult | 26 | 2022 | 30554 | 0.280 |
Why?
|
| Vasoconstriction | 2 | 2018 | 177 | 0.280 |
Why?
|
| Nuclear Proteins | 2 | 2001 | 591 | 0.280 |
Why?
|
| Drug Therapy, Combination | 3 | 2021 | 951 | 0.280 |
Why?
|
| Cell Differentiation | 4 | 2004 | 1701 | 0.280 |
Why?
|
| Echocardiography | 4 | 2020 | 553 | 0.280 |
Why?
|
| Citrate (si)-Synthase | 3 | 2021 | 46 | 0.280 |
Why?
|
| Receptor, Insulin | 3 | 1996 | 93 | 0.270 |
Why?
|
| Arteriosclerosis | 2 | 2003 | 83 | 0.270 |
Why?
|
| Sulfonylurea Compounds | 3 | 2021 | 44 | 0.260 |
Why?
|
| Biomarkers | 6 | 2023 | 3408 | 0.260 |
Why?
|
| Peptide Fragments | 3 | 2021 | 666 | 0.260 |
Why?
|
| Incretins | 2 | 2017 | 15 | 0.260 |
Why?
|
| Glycation End Products, Advanced | 1 | 2006 | 57 | 0.260 |
Why?
|
| Myocardial Contraction | 2 | 2020 | 313 | 0.250 |
Why?
|
| Down-Regulation | 2 | 2010 | 594 | 0.250 |
Why?
|
| Mitogen-Activated Protein Kinases | 4 | 2009 | 278 | 0.250 |
Why?
|
| Pediatric Obesity | 3 | 2017 | 489 | 0.250 |
Why?
|
| Diabetic Nephropathies | 2 | 2020 | 234 | 0.240 |
Why?
|
| Kinetics | 9 | 2017 | 1551 | 0.240 |
Why?
|
| Ventricular Function, Left | 2 | 2020 | 467 | 0.240 |
Why?
|
| Reactive Oxygen Species | 2 | 2022 | 531 | 0.240 |
Why?
|
| Monosaccharide Transport Proteins | 4 | 2001 | 45 | 0.240 |
Why?
|
| Lipids | 4 | 2022 | 580 | 0.240 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2004 | 34 | 0.230 |
Why?
|
| Time Management | 1 | 2004 | 18 | 0.230 |
Why?
|
| Middle Aged | 19 | 2020 | 26738 | 0.230 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2003 | 14 | 0.220 |
Why?
|
| Case-Control Studies | 6 | 2023 | 3004 | 0.220 |
Why?
|
| Double-Blind Method | 6 | 2019 | 1660 | 0.220 |
Why?
|
| Coronary Disease | 2 | 2003 | 348 | 0.220 |
Why?
|
| Intermediate Filaments | 1 | 2023 | 46 | 0.220 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2003 | 88 | 0.220 |
Why?
|
| Neurofilament Proteins | 1 | 2023 | 34 | 0.210 |
Why?
|
| Proto-Oncogene Proteins c-akt | 6 | 2013 | 398 | 0.210 |
Why?
|
| Life Style | 2 | 2023 | 430 | 0.210 |
Why?
|
| Brachial Artery | 3 | 2019 | 176 | 0.200 |
Why?
|
| Young Adult | 13 | 2021 | 10472 | 0.200 |
Why?
|
| Transcription Factors | 6 | 2012 | 1528 | 0.200 |
Why?
|
| Diastole | 2 | 2020 | 130 | 0.200 |
Why?
|
| Physical Fitness | 3 | 2013 | 179 | 0.200 |
Why?
|
| Autophagy | 2 | 2016 | 235 | 0.200 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2002 | 40 | 0.200 |
Why?
|
| Sitagliptin Phosphate | 2 | 2019 | 30 | 0.200 |
Why?
|
| Ecdysterone | 1 | 2001 | 3 | 0.200 |
Why?
|
| Mitochondrial Proteins | 2 | 2015 | 219 | 0.190 |
Why?
|
| Overnutrition | 1 | 2022 | 30 | 0.190 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 4 | 2001 | 228 | 0.190 |
Why?
|
| Nitric Oxide Synthase | 1 | 2022 | 209 | 0.190 |
Why?
|
| Faculty, Medical | 1 | 2004 | 228 | 0.190 |
Why?
|
| Exercise Test | 7 | 2016 | 544 | 0.190 |
Why?
|
| Cattle | 4 | 2009 | 920 | 0.190 |
Why?
|
| Academic Medical Centers | 1 | 2004 | 411 | 0.190 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2021 | 64 | 0.190 |
Why?
|
| Age Factors | 3 | 2021 | 2894 | 0.190 |
Why?
|
| Social Determinants of Health | 1 | 2023 | 137 | 0.190 |
Why?
|
| Triglycerides | 4 | 2013 | 467 | 0.180 |
Why?
|
| Muscle Contraction | 3 | 2017 | 389 | 0.180 |
Why?
|
| Glutathione | 1 | 2022 | 293 | 0.180 |
Why?
|
| Comorbidity | 3 | 2021 | 1448 | 0.180 |
Why?
|
| Aorta, Thoracic | 1 | 2023 | 256 | 0.180 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 2 | 1999 | 172 | 0.180 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2021 | 138 | 0.180 |
Why?
|
| Glycopeptides | 1 | 2021 | 43 | 0.180 |
Why?
|
| Protein Kinases | 2 | 2020 | 307 | 0.180 |
Why?
|
| Antimycin A | 1 | 2020 | 13 | 0.180 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2021 | 94 | 0.180 |
Why?
|
| Clinical Trials as Topic | 2 | 2022 | 932 | 0.180 |
Why?
|
| Mice | 18 | 2022 | 14872 | 0.170 |
Why?
|
| Body Mass Index | 6 | 2018 | 1959 | 0.170 |
Why?
|
| Electron Transport Complex I | 1 | 2020 | 33 | 0.170 |
Why?
|
| Patient Participation | 1 | 2023 | 359 | 0.170 |
Why?
|
| Thrombosis | 2 | 2002 | 298 | 0.170 |
Why?
|
| Congresses as Topic | 2 | 2020 | 195 | 0.170 |
Why?
|
| Apoptosis | 3 | 2007 | 2363 | 0.170 |
Why?
|
| Thiazoles | 2 | 2002 | 110 | 0.170 |
Why?
|
| Thinness | 3 | 2021 | 87 | 0.170 |
Why?
|
| Aged | 14 | 2022 | 19074 | 0.170 |
Why?
|
| Genes, bcl-2 | 1 | 1999 | 20 | 0.170 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 4 | 2010 | 260 | 0.170 |
Why?
|
| Fibroblasts | 4 | 2016 | 838 | 0.170 |
Why?
|
| Perfusion | 2 | 2018 | 148 | 0.170 |
Why?
|
| Animal Nutritional Physiological Phenomena | 1 | 1999 | 12 | 0.170 |
Why?
|
| Cell Line | 8 | 2016 | 2637 | 0.170 |
Why?
|
| Microscopy, Fluorescence | 3 | 2018 | 396 | 0.170 |
Why?
|
| Inservice Training | 1 | 2020 | 105 | 0.160 |
Why?
|
| Transfection | 6 | 2007 | 866 | 0.160 |
Why?
|
| Oxidation-Reduction | 3 | 2020 | 923 | 0.160 |
Why?
|
| Treatment Outcome | 7 | 2022 | 9088 | 0.160 |
Why?
|
| Practice Guidelines as Topic | 3 | 2021 | 1395 | 0.160 |
Why?
|
| PPAR gamma | 3 | 2022 | 182 | 0.160 |
Why?
|
| Heart Diseases | 1 | 2022 | 331 | 0.160 |
Why?
|
| Voltage-Dependent Anion Channel 1 | 2 | 2021 | 9 | 0.160 |
Why?
|
| Echocardiography, Doppler | 3 | 2016 | 92 | 0.160 |
Why?
|
| Deoxyglucose | 3 | 1993 | 43 | 0.160 |
Why?
|
| Mentors | 1 | 2020 | 156 | 0.160 |
Why?
|
| Microscopy, Video | 1 | 2018 | 26 | 0.150 |
Why?
|
| Homocysteine | 1 | 2019 | 136 | 0.150 |
Why?
|
| Carbohydrates | 1 | 2018 | 55 | 0.150 |
Why?
|
| Weight Gain | 1 | 2021 | 453 | 0.150 |
Why?
|
| Venoms | 2 | 2016 | 30 | 0.150 |
Why?
|
| Bicycling | 2 | 2017 | 86 | 0.150 |
Why?
|
| Platelet-Derived Growth Factor | 2 | 2010 | 82 | 0.150 |
Why?
|
| Hemoglobins | 3 | 2017 | 315 | 0.150 |
Why?
|
| Automation | 1 | 2018 | 74 | 0.150 |
Why?
|
| DNA-Binding Proteins | 2 | 1995 | 1314 | 0.150 |
Why?
|
| Interprofessional Relations | 1 | 2020 | 249 | 0.150 |
Why?
|
| Cardiotonic Agents | 1 | 2018 | 119 | 0.150 |
Why?
|
| Mitochondria, Heart | 1 | 2018 | 73 | 0.150 |
Why?
|
| Cysteine | 1 | 2019 | 171 | 0.150 |
Why?
|
| Glucose Clamp Technique | 4 | 2016 | 181 | 0.150 |
Why?
|
| Superoxide Dismutase | 3 | 2021 | 306 | 0.150 |
Why?
|
| Convection | 1 | 2017 | 7 | 0.150 |
Why?
|
| Serine | 5 | 2021 | 126 | 0.150 |
Why?
|
| Dietary Fats | 3 | 2023 | 287 | 0.140 |
Why?
|
| United States | 9 | 2022 | 12186 | 0.140 |
Why?
|
| Capillary Resistance | 1 | 2017 | 5 | 0.140 |
Why?
|
| Combined Modality Therapy | 2 | 2017 | 1121 | 0.140 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2018 | 106 | 0.140 |
Why?
|
| Blood Pressure | 6 | 2021 | 1538 | 0.140 |
Why?
|
| Inflammasomes | 1 | 2018 | 115 | 0.140 |
Why?
|
| Oxyhemoglobins | 1 | 2017 | 20 | 0.140 |
Why?
|
| Incidence | 2 | 2023 | 2313 | 0.140 |
Why?
|
| Phosphatidylinositol 3-Kinases | 5 | 2023 | 329 | 0.140 |
Why?
|
| Heart Failure | 1 | 2010 | 1945 | 0.140 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 238 | 0.140 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2010 | 157 | 0.140 |
Why?
|
| Diffusion | 1 | 2017 | 119 | 0.140 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2017 | 47 | 0.140 |
Why?
|
| Albuminuria | 2 | 2020 | 164 | 0.140 |
Why?
|
| Ventricular Fibrillation | 1 | 2017 | 51 | 0.140 |
Why?
|
| Neoplasm Proteins | 1 | 2000 | 385 | 0.140 |
Why?
|
| Hypoxia | 4 | 2013 | 958 | 0.140 |
Why?
|
| Healthy Lifestyle | 1 | 2017 | 30 | 0.140 |
Why?
|
| Leptin | 2 | 2017 | 210 | 0.140 |
Why?
|
| Fetal Growth Retardation | 1 | 2021 | 468 | 0.140 |
Why?
|
| Disease | 1 | 2017 | 85 | 0.140 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2022 | 452 | 0.130 |
Why?
|
| Adiponectin | 2 | 2016 | 213 | 0.130 |
Why?
|
| Blood Viscosity | 1 | 2016 | 16 | 0.130 |
Why?
|
| Kidney | 4 | 2021 | 1188 | 0.130 |
Why?
|
| Pregnancy | 5 | 2022 | 5520 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2013 | 785 | 0.130 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2021 | 486 | 0.130 |
Why?
|
| MAP Kinase Signaling System | 4 | 2013 | 276 | 0.130 |
Why?
|
| Swine, Miniature | 2 | 2013 | 71 | 0.130 |
Why?
|
| Luteinizing Hormone | 1 | 2017 | 169 | 0.130 |
Why?
|
| Recombinant Fusion Proteins | 6 | 2016 | 616 | 0.130 |
Why?
|
| Electron Transport Complex IV | 1 | 2016 | 53 | 0.130 |
Why?
|
| Immediate-Early Proteins | 1 | 2016 | 52 | 0.130 |
Why?
|
| Prospective Studies | 4 | 2022 | 6220 | 0.130 |
Why?
|
| Nerve Tissue Proteins | 1 | 2000 | 530 | 0.130 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2016 | 473 | 0.130 |
Why?
|
| Menopause | 1 | 2019 | 271 | 0.130 |
Why?
|
| Quality of Life | 2 | 2021 | 2353 | 0.130 |
Why?
|
| Vascular Resistance | 1 | 2017 | 337 | 0.130 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2017 | 216 | 0.130 |
Why?
|
| Forearm | 2 | 2015 | 112 | 0.130 |
Why?
|
| Cost of Illness | 1 | 2018 | 254 | 0.130 |
Why?
|
| Chromans | 1 | 1995 | 21 | 0.130 |
Why?
|
| Goals | 1 | 2017 | 147 | 0.130 |
Why?
|
| Islets of Langerhans | 4 | 2007 | 728 | 0.130 |
Why?
|
| Capillary Permeability | 1 | 2016 | 139 | 0.130 |
Why?
|
| Viral Envelope Proteins | 1 | 2016 | 73 | 0.130 |
Why?
|
| AMP-Activated Protein Kinases | 2 | 2017 | 172 | 0.130 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2016 | 70 | 0.130 |
Why?
|
| PC12 Cells | 3 | 2000 | 37 | 0.130 |
Why?
|
| Insulin-Secreting Cells | 1 | 2019 | 317 | 0.130 |
Why?
|
| Adiposity | 2 | 2017 | 458 | 0.120 |
Why?
|
| Genes, Reporter | 4 | 2016 | 257 | 0.120 |
Why?
|
| Biological Assay | 1 | 2016 | 112 | 0.120 |
Why?
|
| Swine | 4 | 2017 | 700 | 0.120 |
Why?
|
| Drug Administration Schedule | 3 | 2014 | 718 | 0.120 |
Why?
|
| Phosphates | 2 | 1993 | 159 | 0.120 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 1995 | 64 | 0.120 |
Why?
|
| Neurons | 1 | 2003 | 1280 | 0.120 |
Why?
|
| Organelle Biogenesis | 1 | 2015 | 15 | 0.120 |
Why?
|
| Myocardium | 1 | 2020 | 913 | 0.120 |
Why?
|
| Hyperandrogenism | 1 | 2015 | 14 | 0.120 |
Why?
|
| Child | 10 | 2021 | 18422 | 0.120 |
Why?
|
| Sleep | 1 | 2020 | 632 | 0.120 |
Why?
|
| Mice, Knockout | 3 | 2018 | 2570 | 0.120 |
Why?
|
| Body Composition | 5 | 2014 | 590 | 0.120 |
Why?
|
| Ventricular Function | 1 | 2015 | 57 | 0.120 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 1994 | 54 | 0.120 |
Why?
|
| Cell Survival | 4 | 2009 | 1021 | 0.120 |
Why?
|
| American Heart Association | 1 | 2015 | 264 | 0.120 |
Why?
|
| Endothelium | 1 | 2015 | 111 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2020 | 3053 | 0.110 |
Why?
|
| Cholesterol, LDL | 3 | 2014 | 307 | 0.110 |
Why?
|
| Myocytes, Cardiac | 2 | 2009 | 449 | 0.110 |
Why?
|
| CREB-Binding Protein | 3 | 2006 | 27 | 0.110 |
Why?
|
| Healthy Volunteers | 1 | 2015 | 197 | 0.110 |
Why?
|
| Cyclic AMP | 3 | 2006 | 227 | 0.110 |
Why?
|
| Retrospective Studies | 4 | 2022 | 12556 | 0.110 |
Why?
|
| Models, Theoretical | 1 | 2017 | 515 | 0.110 |
Why?
|
| Host-Pathogen Interactions | 1 | 2016 | 295 | 0.110 |
Why?
|
| Free Radical Scavengers | 2 | 2011 | 78 | 0.110 |
Why?
|
| Prevalence | 1 | 2019 | 2251 | 0.110 |
Why?
|
| Electron Transport Chain Complex Proteins | 1 | 2013 | 18 | 0.110 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 2013 | 38 | 0.110 |
Why?
|
| Reaction Time | 1 | 2015 | 376 | 0.110 |
Why?
|
| rho-Associated Kinases | 1 | 2013 | 80 | 0.110 |
Why?
|
| Blotting, Western | 6 | 2011 | 1147 | 0.110 |
Why?
|
| Peptides | 2 | 2016 | 848 | 0.110 |
Why?
|
| Disease Management | 1 | 2017 | 560 | 0.110 |
Why?
|
| Uncoupling Protein 3 | 1 | 2012 | 10 | 0.110 |
Why?
|
| Hypertension, Pulmonary | 4 | 2013 | 1729 | 0.100 |
Why?
|
| Rats, Mutant Strains | 1 | 2012 | 25 | 0.100 |
Why?
|
| Rats, Inbred SHR | 2 | 2010 | 41 | 0.100 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2015 | 141 | 0.100 |
Why?
|
| Cytokines | 3 | 2012 | 1841 | 0.100 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2009 | 1140 | 0.100 |
Why?
|
| Herpesvirus 3, Human | 1 | 2016 | 378 | 0.100 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2013 | 95 | 0.100 |
Why?
|
| Heterozygote | 1 | 2013 | 251 | 0.100 |
Why?
|
| Ion Channels | 1 | 2012 | 123 | 0.100 |
Why?
|
| Lymphocytosis | 1 | 1992 | 9 | 0.100 |
Why?
|
| Enzyme Activation | 4 | 2010 | 785 | 0.100 |
Why?
|
| Hydrogen Peroxide | 2 | 2011 | 288 | 0.100 |
Why?
|
| Pituitary Diseases | 1 | 1992 | 22 | 0.100 |
Why?
|
| Gene Expression Regulation | 4 | 2016 | 2320 | 0.100 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 2 | 2010 | 144 | 0.100 |
Why?
|
| 3T3 Cells | 4 | 2000 | 140 | 0.100 |
Why?
|
| Gene Deletion | 1 | 2013 | 356 | 0.090 |
Why?
|
| Erythrocytes | 1 | 2016 | 591 | 0.090 |
Why?
|
| Rats, Inbred WKY | 4 | 2013 | 32 | 0.090 |
Why?
|
| Anticholesteremic Agents | 1 | 2012 | 128 | 0.090 |
Why?
|
| Fatty Acids | 2 | 2018 | 381 | 0.090 |
Why?
|
| Mitogens | 2 | 2009 | 58 | 0.090 |
Why?
|
| Vitamin D | 1 | 2013 | 341 | 0.090 |
Why?
|
| Cross-Sectional Studies | 5 | 2015 | 4410 | 0.090 |
Why?
|
| Longevity | 2 | 2022 | 137 | 0.090 |
Why?
|
| Casein Kinase II | 1 | 2010 | 21 | 0.090 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2009 | 102 | 0.090 |
Why?
|
| Placebos | 3 | 2019 | 197 | 0.090 |
Why?
|
| Diabetes, Gestational | 1 | 2014 | 281 | 0.090 |
Why?
|
| Receptors, LDL | 1 | 2010 | 38 | 0.090 |
Why?
|
| Dexamethasone | 1 | 1992 | 317 | 0.080 |
Why?
|
| Uracil | 1 | 2009 | 28 | 0.080 |
Why?
|
| RNA-Binding Proteins | 1 | 2012 | 345 | 0.080 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 2 | 2007 | 54 | 0.080 |
Why?
|
| RNA, Messenger | 4 | 2006 | 2553 | 0.080 |
Why?
|
| Calcium | 2 | 1993 | 1108 | 0.080 |
Why?
|
| Receptors, Glucagon | 1 | 2009 | 23 | 0.080 |
Why?
|
| Antihypertensive Agents | 1 | 2012 | 429 | 0.080 |
Why?
|
| Transcription, Genetic | 4 | 2009 | 1313 | 0.080 |
Why?
|
| Oncogene Proteins | 1 | 2009 | 53 | 0.080 |
Why?
|
| Cardiac Output, Low | 1 | 2009 | 64 | 0.080 |
Why?
|
| Diet | 4 | 2019 | 1080 | 0.080 |
Why?
|
| Autoimmune Diseases | 1 | 1992 | 382 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 3 | 2021 | 4694 | 0.080 |
Why?
|
| Physical Exertion | 1 | 2009 | 209 | 0.080 |
Why?
|
| Heart | 2 | 2024 | 612 | 0.080 |
Why?
|
| Piperidines | 1 | 2009 | 160 | 0.080 |
Why?
|
| C-Reactive Protein | 2 | 2009 | 362 | 0.070 |
Why?
|
| Time Factors | 3 | 2014 | 6116 | 0.070 |
Why?
|
| Gene Expression | 1 | 2013 | 1421 | 0.070 |
Why?
|
| Physical Endurance | 1 | 2009 | 232 | 0.070 |
Why?
|
| Genes, Dominant | 2 | 2007 | 94 | 0.070 |
Why?
|
| Enzyme Inhibitors | 3 | 2013 | 750 | 0.070 |
Why?
|
| Pregnancy Complications | 1 | 1992 | 429 | 0.070 |
Why?
|
| HIV Infections | 1 | 2021 | 2469 | 0.070 |
Why?
|
| Brain | 1 | 2018 | 2371 | 0.070 |
Why?
|
| Sequence Deletion | 2 | 1999 | 167 | 0.070 |
Why?
|
| Disease Progression | 2 | 2019 | 2381 | 0.070 |
Why?
|
| Vasodilator Agents | 2 | 2013 | 302 | 0.070 |
Why?
|
| Perception | 1 | 2009 | 311 | 0.070 |
Why?
|
| Luciferases | 3 | 2005 | 142 | 0.070 |
Why?
|
| Cholesterol | 2 | 2013 | 367 | 0.070 |
Why?
|
| Sports | 1 | 2009 | 187 | 0.070 |
Why?
|
| In Vitro Techniques | 2 | 2001 | 1016 | 0.070 |
Why?
|
| Cell Proliferation | 5 | 2013 | 2187 | 0.070 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2009 | 388 | 0.070 |
Why?
|
| Creatinine | 2 | 2020 | 425 | 0.070 |
Why?
|
| Receptor for Advanced Glycation End Products | 1 | 2006 | 29 | 0.070 |
Why?
|
| Fibrinolysis | 3 | 2003 | 158 | 0.070 |
Why?
|
| Oxidants | 2 | 2005 | 112 | 0.070 |
Why?
|
| Food Deprivation | 1 | 2006 | 24 | 0.060 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2006 | 133 | 0.060 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2007 | 351 | 0.060 |
Why?
|
| Activating Transcription Factor 1 | 2 | 1995 | 9 | 0.060 |
Why?
|
| Fetus | 2 | 2021 | 700 | 0.060 |
Why?
|
| Receptors, Immunologic | 1 | 2006 | 201 | 0.060 |
Why?
|
| Glomerular Filtration Rate | 2 | 2020 | 604 | 0.060 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2005 | 113 | 0.060 |
Why?
|
| Interleukin-10 | 1 | 2006 | 299 | 0.060 |
Why?
|
| Fasting | 1 | 2005 | 241 | 0.060 |
Why?
|
| Olfactory Mucosa | 1 | 2004 | 60 | 0.060 |
Why?
|
| Neurons, Afferent | 1 | 2004 | 85 | 0.060 |
Why?
|
| Anthracenes | 1 | 2003 | 27 | 0.050 |
Why?
|
| Cell Hypoxia | 2 | 2017 | 221 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 2765 | 0.050 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2003 | 35 | 0.050 |
Why?
|
| Sucrose | 1 | 2023 | 92 | 0.050 |
Why?
|
| Rats, Zucker | 2 | 2017 | 27 | 0.050 |
Why?
|
| Glucose Oxidase | 1 | 2003 | 18 | 0.050 |
Why?
|
| Protein Isoforms | 1 | 2004 | 338 | 0.050 |
Why?
|
| Arteries | 2 | 2016 | 247 | 0.050 |
Why?
|
| Tyrosine | 1 | 2004 | 214 | 0.050 |
Why?
|
| Bromocriptine | 1 | 2022 | 26 | 0.050 |
Why?
|
| Up-Regulation | 2 | 2010 | 808 | 0.050 |
Why?
|
| Lipid Metabolism | 2 | 2016 | 444 | 0.050 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2003 | 83 | 0.050 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2003 | 68 | 0.050 |
Why?
|
| Vitamin E | 1 | 2003 | 110 | 0.050 |
Why?
|
| Adult Children | 1 | 2022 | 21 | 0.050 |
Why?
|
| Regeneration | 1 | 2004 | 160 | 0.050 |
Why?
|
| Diet, High-Fat | 1 | 2023 | 225 | 0.050 |
Why?
|
| Computer Simulation | 2 | 2017 | 873 | 0.050 |
Why?
|
| Ascorbic Acid | 1 | 2003 | 110 | 0.050 |
Why?
|
| Fetal Heart | 1 | 2022 | 37 | 0.050 |
Why?
|
| Carnitine | 1 | 2022 | 62 | 0.050 |
Why?
|
| Immunohistochemistry | 2 | 2007 | 1629 | 0.050 |
Why?
|
| Genetic Therapy | 1 | 2003 | 257 | 0.050 |
Why?
|
| Mice, Obese | 1 | 2021 | 53 | 0.050 |
Why?
|
| Parathyroid Hormone | 2 | 1993 | 96 | 0.050 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 2 | 2001 | 192 | 0.050 |
Why?
|
| Circadian Rhythm | 2 | 2020 | 356 | 0.050 |
Why?
|
| Base Sequence | 2 | 2009 | 2114 | 0.050 |
Why?
|
| Aromatase Inhibitors | 1 | 2021 | 49 | 0.050 |
Why?
|
| Cell Death | 2 | 2016 | 323 | 0.050 |
Why?
|
| Arginine | 1 | 2003 | 238 | 0.050 |
Why?
|
| Housing | 1 | 2022 | 114 | 0.050 |
Why?
|
| Transcriptional Activation | 2 | 2003 | 337 | 0.050 |
Why?
|
| Respiration | 1 | 2022 | 180 | 0.050 |
Why?
|
| Cardiomegaly | 1 | 2022 | 157 | 0.050 |
Why?
|
| Cross-Over Studies | 1 | 2022 | 440 | 0.050 |
Why?
|
| Heart Function Tests | 2 | 2013 | 58 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2010 | 2968 | 0.050 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2022 | 168 | 0.050 |
Why?
|
| Green Fluorescent Proteins | 2 | 2016 | 371 | 0.050 |
Why?
|
| Medicare | 2 | 2022 | 665 | 0.040 |
Why?
|
| Tamoxifen | 1 | 2021 | 191 | 0.040 |
Why?
|
| Molecular Sequence Data | 2 | 2009 | 2785 | 0.040 |
Why?
|
| Poverty | 1 | 2004 | 442 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2001 | 397 | 0.040 |
Why?
|
| Placental Insufficiency | 1 | 2021 | 102 | 0.040 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2001 | 270 | 0.040 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2021 | 185 | 0.040 |
Why?
|
| Myelin P2 Protein | 1 | 2000 | 2 | 0.040 |
Why?
|
| Fatty Acid-Binding Protein 7 | 1 | 2000 | 3 | 0.040 |
Why?
|
| Phenylbutazone | 1 | 2020 | 2 | 0.040 |
Why?
|
| Tolbutamide | 1 | 2020 | 4 | 0.040 |
Why?
|
| Bucladesine | 1 | 2000 | 24 | 0.040 |
Why?
|
| Consensus Sequence | 1 | 2000 | 70 | 0.040 |
Why?
|
| Oxazoles | 1 | 2020 | 29 | 0.040 |
Why?
|
| Hypertrophy, Right Ventricular | 2 | 2013 | 141 | 0.040 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2000 | 152 | 0.040 |
Why?
|
| Mutation | 2 | 2007 | 3346 | 0.040 |
Why?
|
| Antigens, Differentiation | 1 | 2000 | 79 | 0.040 |
Why?
|
| Linear Models | 2 | 2014 | 768 | 0.040 |
Why?
|
| Systole | 1 | 2020 | 171 | 0.040 |
Why?
|
| Government Regulation | 1 | 2020 | 46 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2021 | 1373 | 0.040 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2000 | 60 | 0.040 |
Why?
|
| Cell Dedifferentiation | 1 | 2019 | 28 | 0.040 |
Why?
|
| Physicians, Women | 1 | 2020 | 55 | 0.040 |
Why?
|
| Proteins | 2 | 1996 | 908 | 0.040 |
Why?
|
| Macrophages | 1 | 2006 | 1263 | 0.040 |
Why?
|
| Muscle Proteins | 1 | 2001 | 210 | 0.040 |
Why?
|
| Cell Transdifferentiation | 1 | 2019 | 31 | 0.040 |
Why?
|
| Open Reading Frames | 1 | 2000 | 117 | 0.040 |
Why?
|
| Sheep | 1 | 2021 | 764 | 0.040 |
Why?
|
| MAP Kinase Kinase 6 | 1 | 1999 | 1 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2022 | 740 | 0.040 |
Why?
|
| Sequence Alignment | 1 | 2000 | 323 | 0.040 |
Why?
|
| Chromogranins | 1 | 1999 | 12 | 0.040 |
Why?
|
| Glycine | 1 | 2020 | 152 | 0.040 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2020 | 172 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2020 | 172 | 0.040 |
Why?
|
| PPAR alpha | 2 | 2010 | 52 | 0.040 |
Why?
|
| Peer Group | 1 | 2020 | 201 | 0.040 |
Why?
|
| Citric Acid Cycle | 1 | 2018 | 43 | 0.040 |
Why?
|
| Pulmonary Circulation | 2 | 2013 | 407 | 0.040 |
Why?
|
| Machine Learning | 1 | 2022 | 316 | 0.040 |
Why?
|
| Chromogranin A | 1 | 1999 | 39 | 0.040 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2018 | 65 | 0.040 |
Why?
|
| Hippocampus | 1 | 2003 | 693 | 0.040 |
Why?
|
| GTP Phosphohydrolases | 1 | 2018 | 65 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-sis | 2 | 2010 | 35 | 0.040 |
Why?
|
| Minority Groups | 1 | 2020 | 227 | 0.040 |
Why?
|
| Career Choice | 1 | 2020 | 177 | 0.040 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2021 | 412 | 0.040 |
Why?
|
| Cloning, Molecular | 1 | 1999 | 522 | 0.040 |
Why?
|
| Phenylephrine | 1 | 2018 | 71 | 0.040 |
Why?
|
| Diet, Western | 1 | 2018 | 66 | 0.040 |
Why?
|
| Hematocrit | 1 | 2018 | 87 | 0.040 |
Why?
|
| Coronary Vessels | 1 | 2020 | 227 | 0.040 |
Why?
|
| Caspase 1 | 1 | 2018 | 140 | 0.040 |
Why?
|
| Flow Cytometry | 1 | 2001 | 1083 | 0.040 |
Why?
|
| Universities | 1 | 2020 | 340 | 0.040 |
Why?
|
| Health Behavior | 1 | 2023 | 704 | 0.040 |
Why?
|
| Antioxidants | 1 | 2001 | 530 | 0.040 |
Why?
|
| Social Media | 1 | 2020 | 131 | 0.040 |
Why?
|
| Cell Membrane | 3 | 2004 | 680 | 0.040 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2018 | 144 | 0.040 |
Why?
|
| Occupational Exposure | 1 | 2020 | 255 | 0.040 |
Why?
|
| Adenosine Triphosphate | 2 | 2017 | 430 | 0.040 |
Why?
|
| Risk | 1 | 2020 | 812 | 0.040 |
Why?
|
| Extracellular Matrix | 2 | 2013 | 436 | 0.030 |
Why?
|
| Postmenopause | 1 | 2019 | 303 | 0.030 |
Why?
|
| Insulin Glargine | 1 | 2017 | 73 | 0.030 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2018 | 220 | 0.030 |
Why?
|
| Binding Sites | 1 | 2000 | 1168 | 0.030 |
Why?
|
| Nutritional Status | 1 | 2019 | 287 | 0.030 |
Why?
|
| Social Support | 1 | 2020 | 528 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2017 | 124 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2020 | 664 | 0.030 |
Why?
|
| Phosphorus Radioisotopes | 2 | 1993 | 27 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 2018 | 370 | 0.030 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 1996 | 41 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 1998 | 850 | 0.030 |
Why?
|
| Estradiol | 1 | 2019 | 455 | 0.030 |
Why?
|
| Placenta | 1 | 2021 | 628 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2000 | 695 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2020 | 4895 | 0.030 |
Why?
|
| Collagen | 2 | 2009 | 415 | 0.030 |
Why?
|
| Myocardial Ischemia | 1 | 2017 | 235 | 0.030 |
Why?
|
| Nitrendipine | 2 | 1993 | 13 | 0.030 |
Why?
|
| Heart Rate | 3 | 2009 | 709 | 0.030 |
Why?
|
| Cytoplasm | 1 | 2016 | 255 | 0.030 |
Why?
|
| Protein Phosphatase 2 | 1 | 1995 | 30 | 0.030 |
Why?
|
| ras Guanine Nucleotide Exchange Factors | 1 | 1995 | 8 | 0.030 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 338 | 0.030 |
Why?
|
| Absorptiometry, Photon | 1 | 2016 | 224 | 0.030 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 330 | 0.030 |
Why?
|
| Lovastatin | 1 | 1995 | 26 | 0.030 |
Why?
|
| Glycogen | 1 | 1995 | 51 | 0.030 |
Why?
|
| Peptide Mapping | 1 | 1994 | 60 | 0.030 |
Why?
|
| Cystatin C | 1 | 2014 | 62 | 0.030 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 1995 | 55 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1999 | 1842 | 0.030 |
Why?
|
| Phosphorus | 1 | 2014 | 82 | 0.030 |
Why?
|
| Stress, Mechanical | 1 | 2016 | 445 | 0.030 |
Why?
|
| Interleukin-6 | 2 | 2009 | 676 | 0.030 |
Why?
|
| Fatty Acid Synthases | 2 | 2006 | 23 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2013 | 26 | 0.030 |
Why?
|
| Rats, Inbred Strains | 2 | 1991 | 362 | 0.030 |
Why?
|
| Lipolysis | 1 | 2013 | 39 | 0.030 |
Why?
|
| Delivery, Obstetric | 1 | 2014 | 118 | 0.030 |
Why?
|
| Biomechanical Phenomena | 1 | 2016 | 669 | 0.030 |
Why?
|
| Carbon Radioisotopes | 1 | 1993 | 36 | 0.030 |
Why?
|
| Protein Stability | 1 | 2013 | 157 | 0.030 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2013 | 56 | 0.030 |
Why?
|
| Acyl Coenzyme A | 1 | 2013 | 30 | 0.030 |
Why?
|
| Body Weight | 1 | 2017 | 869 | 0.030 |
Why?
|
| Adolescent Health Services | 1 | 2013 | 68 | 0.030 |
Why?
|
| Registries | 1 | 2020 | 1768 | 0.030 |
Why?
|
| Reference Values | 2 | 2007 | 743 | 0.030 |
Why?
|
| Cardiolipins | 1 | 2013 | 71 | 0.030 |
Why?
|
| Colorado | 2 | 2017 | 4100 | 0.030 |
Why?
|
| Immunoblotting | 2 | 2007 | 283 | 0.020 |
Why?
|
| Physicians | 1 | 2020 | 772 | 0.020 |
Why?
|
| Pandemics | 1 | 2020 | 1320 | 0.020 |
Why?
|
| Optic Chiasm | 1 | 1992 | 18 | 0.020 |
Why?
|
| Nerve Compression Syndromes | 1 | 1992 | 25 | 0.020 |
Why?
|
| Premenopause | 2 | 2003 | 106 | 0.020 |
Why?
|
| Mice, Inbred NOD | 2 | 2004 | 555 | 0.020 |
Why?
|
| Muscle Strength | 1 | 2014 | 271 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 1995 | 1230 | 0.020 |
Why?
|
| Thyrotropin | 1 | 1992 | 99 | 0.020 |
Why?
|
| Hypothyroidism | 1 | 1992 | 64 | 0.020 |
Why?
|
| Heart Ventricles | 1 | 2016 | 712 | 0.020 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 1992 | 50 | 0.020 |
Why?
|
| Potassium | 1 | 1991 | 128 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 1430 | 0.020 |
Why?
|
| Headache | 1 | 1992 | 133 | 0.020 |
Why?
|
| Protein Binding | 1 | 2016 | 1890 | 0.020 |
Why?
|
| Inflammation | 3 | 2009 | 2480 | 0.020 |
Why?
|
| Vision Disorders | 1 | 1992 | 130 | 0.020 |
Why?
|
| Pituitary Neoplasms | 1 | 1992 | 157 | 0.020 |
Why?
|
| Child Development | 1 | 2014 | 385 | 0.020 |
Why?
|
| Adenoma | 1 | 1992 | 189 | 0.020 |
Why?
|
| Cytosol | 1 | 2010 | 208 | 0.020 |
Why?
|
| CCN Intercellular Signaling Proteins | 1 | 2009 | 5 | 0.020 |
Why?
|
| Body Fat Distribution | 1 | 2009 | 46 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2011 | 535 | 0.020 |
Why?
|
| Plethysmography | 1 | 2009 | 103 | 0.020 |
Why?
|
| Placebo Effect | 1 | 2009 | 52 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2011 | 343 | 0.020 |
Why?
|
| Swimming | 1 | 2009 | 44 | 0.020 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2009 | 63 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2020 | 4624 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2009 | 249 | 0.020 |
Why?
|
| Hormones | 1 | 2009 | 132 | 0.020 |
Why?
|
| Puberty | 1 | 2009 | 135 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 4411 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 1992 | 1342 | 0.020 |
Why?
|
| Myoglobin | 1 | 2007 | 14 | 0.020 |
Why?
|
| Betacellulin | 1 | 2007 | 6 | 0.020 |
Why?
|
| Saliva | 1 | 2009 | 188 | 0.020 |
Why?
|
| Protein Transport | 1 | 2009 | 395 | 0.020 |
Why?
|
| Fenofibrate | 1 | 2007 | 24 | 0.020 |
Why?
|
| Caspase 9 | 1 | 2007 | 48 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2007 | 119 | 0.020 |
Why?
|
| Hypolipidemic Agents | 1 | 2007 | 86 | 0.020 |
Why?
|
| Adenylyl Cyclase Inhibitors | 1 | 2006 | 5 | 0.020 |
Why?
|
| Running | 1 | 2009 | 207 | 0.020 |
Why?
|
| Elastin | 1 | 2006 | 78 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2006 | 63 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2009 | 6347 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2007 | 184 | 0.020 |
Why?
|
| Intracellular Membranes | 1 | 2006 | 73 | 0.020 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2006 | 45 | 0.020 |
Why?
|
| Proteasome Inhibitors | 1 | 2006 | 41 | 0.020 |
Why?
|
| Heme Oxygenase-1 | 1 | 2006 | 52 | 0.020 |
Why?
|
| Haptoglobins | 1 | 2006 | 47 | 0.020 |
Why?
|
| Receptors, IgG | 1 | 2006 | 67 | 0.020 |
Why?
|
| Ubiquitin | 1 | 2006 | 57 | 0.020 |
Why?
|
| Caspases | 1 | 2007 | 245 | 0.020 |
Why?
|
| Cadaver | 1 | 2007 | 299 | 0.020 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2006 | 110 | 0.020 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2006 | 84 | 0.020 |
Why?
|
| RNA Stability | 1 | 2006 | 90 | 0.020 |
Why?
|
| Macaca mulatta | 1 | 2006 | 131 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2006 | 237 | 0.020 |
Why?
|
| Acetylcysteine | 1 | 2006 | 141 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2009 | 641 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2005 | 396 | 0.010 |
Why?
|
| Cholesterol, HDL | 1 | 2005 | 183 | 0.010 |
Why?
|
| Antibodies | 1 | 2006 | 371 | 0.010 |
Why?
|
| Mice, Congenic | 1 | 2004 | 21 | 0.010 |
Why?
|
| Lung | 1 | 2016 | 3561 | 0.010 |
Why?
|
| Receptors, Odorant | 1 | 2004 | 35 | 0.010 |
Why?
|
| Molecular Mimicry | 1 | 2003 | 35 | 0.010 |
Why?
|
| Patient Selection | 1 | 2007 | 641 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 923 | 0.010 |
Why?
|
| Membrane Potentials | 1 | 2004 | 248 | 0.010 |
Why?
|
| Smell | 1 | 2004 | 111 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 2006 | 823 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2004 | 289 | 0.010 |
Why?
|
| Imidazoles | 1 | 2003 | 208 | 0.010 |
Why?
|
| Serum Globulins | 1 | 2002 | 4 | 0.010 |
Why?
|
| Data Collection | 1 | 2005 | 620 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 2009 | 927 | 0.010 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2002 | 83 | 0.010 |
Why?
|
| Protein Prenylation | 1 | 2001 | 19 | 0.010 |
Why?
|
| Infant | 1 | 2014 | 7964 | 0.010 |
Why?
|
| Glucose Transporter Type 4 | 1 | 2001 | 36 | 0.010 |
Why?
|
| Fibrinogen | 1 | 2002 | 154 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2003 | 728 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2004 | 1079 | 0.010 |
Why?
|
| Pyridines | 1 | 2003 | 425 | 0.010 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2002 | 225 | 0.010 |
Why?
|
| Densitometry | 1 | 1998 | 29 | 0.010 |
Why?
|
| Autonomic Nervous System | 1 | 1998 | 66 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1986 | 1356 | 0.010 |
Why?
|
| Alcohol Drinking | 1 | 2003 | 651 | 0.010 |
Why?
|
| Lactic Acid | 1 | 1998 | 275 | 0.010 |
Why?
|
| Immunosorbent Techniques | 1 | 1996 | 17 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 1996 | 43 | 0.010 |
Why?
|
| ras GTPase-Activating Proteins | 1 | 1996 | 13 | 0.010 |
Why?
|
| Smoking | 1 | 2003 | 1383 | 0.010 |
Why?
|
| Chromones | 1 | 1996 | 35 | 0.010 |
Why?
|
| Guanosine Triphosphate | 1 | 1996 | 85 | 0.010 |
Why?
|
| CHO Cells | 1 | 1996 | 138 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 1996 | 113 | 0.010 |
Why?
|
| GTPase-Activating Proteins | 1 | 1996 | 72 | 0.010 |
Why?
|
| Cricetinae | 1 | 1996 | 253 | 0.010 |
Why?
|
| Morpholines | 1 | 1996 | 102 | 0.010 |
Why?
|
| Primary Health Care | 1 | 2004 | 1514 | 0.010 |
Why?
|
| Thapsigargin | 1 | 1993 | 18 | 0.010 |
Why?
|
| Thionucleotides | 1 | 1993 | 34 | 0.010 |
Why?
|
| Calcium-Transporting ATPases | 1 | 1993 | 34 | 0.010 |
Why?
|
| Terpenes | 1 | 1993 | 21 | 0.010 |
Why?
|
| Neoplasms | 1 | 1986 | 2097 | 0.010 |
Why?
|
| Biological Transport | 1 | 1993 | 374 | 0.010 |
Why?
|
| Disulfiram | 1 | 1986 | 13 | 0.000 |
Why?
|
| Drug Evaluation | 1 | 1986 | 77 | 0.000 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1986 | 161 | 0.000 |
Why?
|
| Cisplatin | 1 | 1986 | 262 | 0.000 |
Why?
|